HZNP [NASD]
Horizon Therapeutics Public Limited Company
Index- P/E45.10 EPS (ttm)2.43 Insider Own1.25% Shs Outstand230.33M Perf Week0.03%
Market Cap25.08B Forward P/E20.28 EPS next Y5.41 Insider Trans-4.44% Shs Float223.96M Perf Month-2.79%
Income574.30M PEG3.76 EPS next Q1.09 Inst Own95.80% Short Float / Ratio2.42% / 1.28 Perf Quarter50.94%
Sales3.70B P/S6.77 EPS this Y25.30% Inst Trans1.83% Short Interest5.43M Perf Half Y58.16%
Book/sh21.85 P/B5.02 EPS next Y13.62% ROA6.50% Target Price116.14 Perf Year20.17%
Cash/sh9.32 P/C11.77 EPS next 5Y12.00% ROE11.80% 52W Range57.84 - 117.49 Perf YTD-3.27%
Dividend- P/FCF19.08 EPS past 5Y33.30% ROI8.50% 52W High-6.31% Beta1.16
Dividend %- Quick Ratio3.70 Sales past 5Y26.90% Gross Margin75.10% 52W Low90.32% ATR0.98
Employees2095 Current Ratio4.00 Sales Q/Q-10.80% Oper. Margin18.30% RSI (14)50.00 Volatility1.21% 0.58%
OptionableYes Debt/Eq0.51 EPS Q/Q-58.30% Profit Margin15.50% Rel Volume0.24 Prev Close109.68
ShortableYes LT Debt/Eq0.51 EarningsMar 01 BMO Payout0.00% Avg Volume4.24M Price110.08
Recom2.50 SMA20-1.76% SMA502.95% SMA20030.94% Volume367,636 Change0.36%
Nov-01-22Initiated H.C. Wainwright Neutral $74
Aug-04-22Downgrade SVB Leerink Outperform → Mkt Perform
Jun-14-22Initiated UBS Buy $139
Jun-06-22Resumed SVB Leerink Mkt Perform $95
May-23-22Initiated SVB Leerink Mkt Perform $95
Mar-15-22Initiated Oppenheimer Outperform $140
Dec-08-21Initiated Wells Fargo Overweight $137
Nov-19-21Upgrade Goldman Neutral → Buy $168
Oct-07-21Resumed Jefferies Buy $132
Mar-22-21Resumed Morgan Stanley Overweight $103
Show Previous Ratings
Jan-30-23 08:00AM
Jan-27-23 04:05PM
Jan-23-23 06:05PM
06:01PM
Jan-18-23 08:00AM
07:08AM Loading…
Jan-17-23 07:08AM
Jan-12-23 05:05PM
Jan-06-23 11:55AM
11:45AM
11:41AM
11:25AM
Jan-04-23 11:30AM
08:00AM
Jan-03-23 12:03PM
11:58AM
09:07AM Loading…
Dec-30-22 09:07AM
Dec-20-22 08:30AM
08:00AM
Dec-13-22 09:25AM
Dec-12-22 05:26PM
03:53PM
12:10PM
11:36AM
11:06AM
10:57AM
10:18AM
10:04AM
09:02AM
08:48AM
01:57AM
09:00AM Loading…
Dec-08-22 09:00AM
08:00AM
Dec-03-22 09:39AM
Dec-01-22 03:24PM
Nov-30-22 11:15AM
10:31AM
09:00AM
07:23AM
03:00AM
Nov-29-22 05:12PM
04:25PM
Nov-23-22 09:40AM
09:36AM
Nov-16-22 08:15AM
08:00AM
Nov-10-22 08:00AM
Nov-09-22 11:05AM
Nov-08-22 10:00AM
08:26AM
Nov-05-22 10:00AM
Nov-02-22 09:33PM
07:00AM
Nov-01-22 09:00AM
Oct-27-22 08:30AM
08:30AM
Oct-26-22 08:00AM
Oct-22-22 10:30AM
Oct-13-22 08:00AM
Oct-12-22 08:00AM
Oct-06-22 10:03AM
08:00AM
Oct-02-22 11:15AM
Sep-29-22 08:00AM
Sep-26-22 06:59AM
Sep-22-22 08:04AM
Sep-21-22 08:04AM
Sep-19-22 08:00AM
Sep-16-22 09:00AM
Sep-14-22 08:00AM
Sep-13-22 08:30AM
Sep-12-22 08:00AM
Sep-09-22 08:00AM
Sep-08-22 08:03AM
Aug-31-22 03:25PM
09:03AM
08:00AM
Aug-29-22 04:00AM
Aug-25-22 08:00AM
Aug-24-22 03:17PM
Aug-22-22 03:01PM
Aug-15-22 04:35PM
08:00AM
Aug-04-22 09:08AM
Aug-03-22 07:00AM
Jul-25-22 08:02AM
Jul-21-22 08:00AM
Jul-11-22 08:00AM
Jul-08-22 08:00AM
Jul-07-22 08:00AM
Jun-27-22 08:58AM
Jun-24-22 12:30PM
Jun-15-22 08:30AM
07:45AM
Jun-11-22 10:00AM
Jun-09-22 08:00AM
Jun-06-22 04:30PM
Jun-02-22 08:00AM
Jun-01-22 08:00AM
May-31-22 04:01PM
08:00AM
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pasternak AndyEVP, Chief Strategy OfficerJan 17Sale113.0327,1293,066,32356,338Jan 18 04:19 PM
Cox AaronEVP, Chief Financial OfficerJan 13Sale113.1736,1484,090,847277Jan 17 08:32 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJan 11Sale113.103,368380,92136,171Jan 12 04:29 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJan 10Sale113.053,368380,75239,539Jan 12 04:29 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJan 06Sale113.295,187587,63549,314Jan 06 05:54 PM
Pasternak AndyEVP, Chief Strategy OfficerDec 13Option Exercise29.5223,251686,37064,216Dec 14 05:10 PM
Pasternak AndyEVP, Chief Strategy OfficerDec 13Sale112.6030,1693,397,17134,047Dec 14 05:10 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerDec 12Sale111.4528,3523,159,69254,501Dec 13 04:12 PM
Clayton Sean M.EVP, General CounselAug 04Buy66.6774549,669745Aug 08 04:18 PM
Pasternak AndyEVP and Chief Business OfficerJul 29Sale82.574,850400,48334,047Jul 29 05:21 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentJul 20Sale85.005,917502,9456,969Jul 20 06:19 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentJul 19Sale85.04907,65312,886Jul 20 06:19 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentJul 07Sale85.01826,97112,976Jul 11 06:03 PM
Pasternak AndyEVP and Chief Business OfficerJun 10Sale85.3676265,04438,897Jun 13 04:19 PM
Walbert Timothy PChairman, President and CEOJun 03Option Exercise22.1425,000553,500460,826Jun 03 07:04 PM
Walbert Timothy PChairman, President and CEOJun 03Sale92.3425,0002,308,468435,826Jun 03 07:04 PM
Walbert Timothy PChairman, President and CEOMay 31Sale92.4825,0002,311,980435,549Jun 02 04:13 PM
Walbert Timothy PChairman, President and CEOMay 20Option Exercise22.1425,000553,500485,549May 20 06:15 PM
Walbert Timothy PChairman, President and CEOMay 20Sale90.0025,0002,250,000460,549May 20 06:15 PM
Walbert Timothy PChairman, President and CEOMay 11Option Exercise22.1417,600389,664478,149May 13 04:31 PM
Walbert Timothy PChairman, President and CEOMay 11Sale90.0017,6001,584,000460,549May 13 04:31 PM
Walbert Timothy PChairman, President and CEOMay 06Option Exercise22.147,400163,836467,949May 10 05:59 PM
Walbert Timothy PChairman, President and CEOMay 06Sale90.867,400672,342460,549May 10 05:59 PM
Walbert Timothy PChairman, President and CEOMay 02Sale96.0425,0002,401,006460,549May 04 04:24 PM
Walbert Timothy PChairman, President and CEOApr 22Option Exercise22.1425,000553,500510,549Apr 22 06:49 PM
Walbert Timothy PChairman, President and CEOApr 22Sale106.5925,0002,664,632485,549Apr 22 06:49 PM
Hoelscher Paul W.EVP, CFOApr 20Option Exercise22.1450,0001,107,00051,049Apr 22 06:47 PM
Hoelscher Paul W.EVP, CFOApr 20Sale114.7150,0005,735,4491,049Apr 22 06:47 PM
Thompson Elizabeth H.Z.EVP, Research & DevelopmentApr 18Sale115.648,098936,45313,058Apr 20 04:13 PM
DesJardin Michael A.EVP, Technical OperationsApr 12Sale113.1220,2142,286,70382,346Apr 14 04:49 PM
Walbert Timothy PChairman, President and CEOApr 08Option Exercise22.1425,000553,500510,549Apr 08 04:11 PM
Walbert Timothy PChairman, President and CEOApr 08Sale112.3825,0002,809,521485,549Apr 08 04:11 PM
Hoelscher Paul W.EVP, CFOApr 06Option Exercise21.27215,3354,580,417216,384Apr 08 04:09 PM
Hoelscher Paul W.EVP, CFOApr 06Sale110.0191,71010,089,02666,673Apr 08 04:09 PM
Hoelscher Paul W.EVP, CFOApr 06Sale110.01215,33523,688,7881,049Apr 08 04:09 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerApr 06Sale110.0242,0094,621,87210,629Apr 08 04:07 PM
Walbert Timothy PChairman, President and CEOMar 30Sale105.2650,0005,262,787485,549Apr 01 04:10 PM
Walbert Timothy PChairman, President and CEOMar 25Option Exercise22.1425,000553,500560,549Mar 25 06:40 PM
Walbert Timothy PChairman, President and CEOMar 25Sale109.3725,0002,734,340535,549Mar 25 06:40 PM
Hoelscher Paul W.EVP, CFOMar 25Sale110.0066372,930158,383Mar 25 06:38 PM
Hoelscher Paul W.EVP, CFOMar 24Sale110.001,481162,910159,046Mar 25 06:38 PM
Hoelscher Paul W.EVP, CFOMar 23Option Exercise15.9626,090416,39627,139Mar 25 06:38 PM
Hoelscher Paul W.EVP, CFOMar 23Sale110.0111,6991,287,018160,527Mar 25 06:38 PM
Hoelscher Paul W.EVP, CFOMar 23Sale110.0026,0902,870,0021,049Mar 25 06:38 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMar 18Option Exercise22.148,531188,87652,638Mar 21 04:25 PM
Walbert Timothy PChairman, President and CEOMar 11Option Exercise22.1425,000553,500560,549Mar 11 05:17 PM
Walbert Timothy PChairman, President and CEOMar 11Sale100.9325,0002,523,314535,549Mar 11 05:17 PM
DesJardin Michael A.EVP, Technical OperationsMar 02Sale97.1935,0003,401,752102,560Mar 04 04:19 PM
Pasternak AndyEVP and Chief Business OfficerFeb 18Sale94.821,313124,49939,659Feb 18 04:42 PM
Walbert Timothy PChairman, President and CEOFeb 11Option Exercise22.1425,000553,500610,549Feb 11 04:16 PM
Walbert Timothy PChairman, President and CEOFeb 11Sale97.4125,0002,435,242585,549Feb 11 04:16 PM